No Data
No Data
Press Release: Acadia Pharmaceuticals to Announce First Quarter Financial Results on May 7, 2025
TD Cowen Maintains ACADIA Pharmaceuticals(ACAD.US) With Buy Rating, Maintains Target Price $35
TD Cowen Sticks to Its Buy Rating for ACADIA Pharmaceuticals (ACAD)
BofA Securities Maintains ACADIA Pharmaceuticals(ACAD.US) With Hold Rating, Maintains Target Price $18
BMO Capital Maintains ACADIA Pharmaceuticals(ACAD.US) With Buy Rating, Cuts Target Price to $24
BofA Securities Maintains ACADIA Pharmaceuticals(ACAD.US) With Hold Rating, Announces Target Price $18